PRX-00023

DRUG3 trials

Sponsors

Epix Pharmaceuticals, Inc., National Institute of Neurological Disorders and Stroke (NINDS)

Conditions

Anxiety DisordersEpilepsyEpilepsy, Temporal LobeMajor Depressive Disorder (MDD)Partial Epilepsy

Phase 2

A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

CompletedNCT00448292

Epix Pharmaceuticals, Inc.Major Depressive Disorder (MDD)

Start: 2007-03-31End: 2007-11-30Target: 330Updated: 2007-11-14

PRX-00023 Therapy in Localization-Related Epilepsy

TerminatedNCT01281956

National Institute of Neurological Disorders and Stroke (NINDS)Epilepsy, Epilepsy, Temporal Lobe, Partial Epilepsy

Start: 2011-01-07End: 2017-10-05Updated: 2018-12-07

Phase 3

A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)

CompletedNCT00248183

Epix Pharmaceuticals, Inc.Anxiety Disorders

Start: 2005-08-31End: 2006-06-30Target: 310Updated: 2008-04-03